Original Research Article
Dec. 30, 2020
Evaluation of Safety, Immunogenicity and Potency of PPR Vaccine
Jaykumar Satav, KVN Rathnakar Reddi, Gopu Akhila, Dahiphale Hanumant, TVS Rao, GS Reddy
Sch J Agric Vet Sci | 244-249
DOI : 10.36347/sjavs.2020.v07i12.001
Peste des Petits Ruminants (PPR) is one of the most economically important, highly contagious, fatal transboundary viral diseases of small ruminants affecting primarily the sheep and goats and caused by PPR virus (PPRV), a member in Morbillivirus genus of family Paramyxoviridae. As we know that prophylaxis using live attenuated vaccines is the primary choice of control measure as the immunity is long lasting. In this study, we evaluated safety, immunogenicity and potency of a live attenuated PPR vaccine manufactured by Brilliant Bio Pharma Private Limited in a freeze-dried form containing vaccine virus titer of 103.5 CCID50/dose. The vaccine safety was tested in goats using 100 times the recommended field dose. In the safety trial, none of the vaccinated animals showed any deviation from physiological norms or fever. In the immunogenicity study, all the sheep and goats vaccinated by subcutaneous route developed virus-neutralizing antibody titer in the range of 1:8 to 1:128 at 21 days post-vaccination (dpv). While, in the potency study, all the vaccinated animals resisted challenge with virulent PPR virus on 21 dpv and demonstrated full protection, while unvaccinated control sheep and goats showed characteristic clinical signs of PPR disease. Overall, the live attenuated PPR vaccine was found to be safe, immunogenic and potent as evident from safety, sero-conversion as well as challenge studies in sheep and goats.